Search

Your search keyword '"Bircan Kayaaslan"' showing total 3 results
Start Over Author "Bircan Kayaaslan" Journal journal of infection and public health
3 results on '"Bircan Kayaaslan"'

1. Response to the letter to the editor

Author

Rahmet Guner, Imran Hasanoglu, Bircan Kayaaslan, Adalet Aypak, Esragul Akinci, Hurrem Bodur, Fatma Eser, Ayse Kaya Kalem, Orhan Kucuksahin, Ihsan Ates, Aliye Bastug, Yasemin Tezer Tekce, Zeynep Bilgic, Fahriye Melis Gursoy, Hatice Nisa Akca, Seval Izdes, Deniz Erdem, Emra Asfuroglu, Habibe Hezer, Hatice Kilic, Musa Civak, Sibel Aydogan, and Turan Buzgan

Subjects
Infectious and parasitic diseases, RC109-216, Public aspects of medicine, RA1-1270
Published
2022
Full Text
View/download PDF

2. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir

Author

Rahmet Guner, Imran Hasanoglu, Bircan Kayaaslan, Adalet Aypak, Esragul Akinci, Hurrem Bodur, Fatma Eser, Ayse Kaya Kalem, Orhan Kucuksahin, Ihsan Ates, Aliye Bastug, Yasemin Tezer Tekce, Zeynep Bilgic, Fahriye Melis Gursoy, Hatice Nisa Akca, Seval Izdes, Deniz Erdem, Emra Asfuroglu, Habibe Hezer, Hatice Kilic, Musa Cıvak, Sibel Aydogan, and Turan Buzgan

Subjects
COVID-19, Treatment, Favipiravir, Hydroxychloroquine, ICU, Infectious and parasitic diseases, RC109-216, Public aspects of medicine, RA1-1270
Abstract

Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective designed observational study conducted in Ankara City Hospital. Patients who were hospitalized between March 15, 2020 and June 1, 2020 in COVID-19 inpatient clinics with laboratory confirmed diagnosis of COVID-19 were included in the study. An inverse probability of treatment weighting (IPTW) for multiple treatment groups approach was used to balance the differences in several variables on admission. Results: Among 2441 patients hospitalized with diagnosis of COVID-19 during the study period, 824 were eligible for the analysis. Median age of patients was 42 (18−93 years). Among all, 347 (43.2%) of the patients had mild disease, 470 (56.8%) had pneumonia. Propensity scores ranged from 0.1841 to 0.9381 in the HCQ group, from 0.03643 to 0.29885 in the favipiravir group, and from 0.03542 to 0.56184 in the HCQ plus favipiravir group. After IPTW for multiple treatment groups was applied, all the covariates in the planned propensity score had weighted standardized effect sizes below 10% which were ranged from 0.005 to 0.092. Multivariate analysis of treatment effect (adjusted effect of treatment) was indicated that there is no statistically significant difference between HCQ, favipiravir, and HCQ plus favipiravir treatment. After using combination of SMOTE and Bootstrap resampling approach, we found no statistically significant difference between HCQ and HCQ plus favipiravir groups in terms of ICU admission. However, compared with the HCQ group, ICU admission rate was statistically significantly higher in the favipiravir group. We obtained the similar results after the sensitivity analysis. Conclusions: HCQ with or without favipiravir treatment is associated with reduced risk of ICU admission compared to favipiravir alone in mild to moderate COVID-19 adult patients.

Published
2021
Full Text
View/download PDF

3. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir

Author

Fahriye Melis Gursoy, Esragül Akinci, Orhan Küçükşahin, Emra Asfuroglu, Hatice Nisa Akca, Habibe Hezer, Hatice Kilic, Fatma Eser, Aliye Bastug, Adalet Aypak, Imran Hasanoglu, Ihsan Ates, Bircan Kayaaslan, Seval Izdes, Hürrem Bodur, Musa Civak, Rahmet Guner, Deniz Erdem, Yasemin Tezer Tekce, Turan Buzgan, Ayse Kaya Kalem, Zeynep Bilgic, and Sibel Aydogan

Subjects
0301 basic medicine, medicine.medical_specialty, Multivariate analysis, 030106 microbiology, Favipiravir, Single Center, Article, law.invention, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, 0302 clinical medicine, law, Internal medicine, medicine, lcsh:RC109-216, 030212 general & internal medicine, business.industry, lcsh:Public aspects of medicine, Public Health, Environmental and Occupational Health, COVID-19, Hydroxychloroquine, lcsh:RA1-1270, General Medicine, Intensive care unit, Icu admission, Treatment, Infectious Diseases, Propensity score matching, ICU, Observational study, business, medicine.drug
Abstract

Background In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods Single center retrospective designed observational study conducted in Ankara City Hospital. Patients who were hospitalized between March 15, 2020 and June 1, 2020 in COVID-19 inpatient clinics with laboratory confirmed diagnosis of COVID-19 were included in the study. An inverse probability of treatment weighting (IPTW) for multiple treatment groups approach was used to balance the differences in several variables on admission. Results Among 2441 patients hospitalized with diagnosis of COVID-19 during the study period, 824 were eligible for the analysis. Median age of patients was 42 (18−93 years). Among all, 347 (43.2%) of the patients had mild disease, 470 (56.8%) had pneumonia. Propensity scores ranged from 0.1841 to 0.9381 in the HCQ group, from 0.03643 to 0.29885 in the favipiravir group, and from 0.03542 to 0.56184 in the HCQ plus favipiravir group. After IPTW for multiple treatment groups was applied, all the covariates in the planned propensity score had weighted standardized effect sizes below 10% which were ranged from 0.005 to 0.092. Multivariate analysis of treatment effect (adjusted effect of treatment) was indicated that there is no statistically significant difference between HCQ, favipiravir, and HCQ plus favipiravir treatment. After using combination of SMOTE and Bootstrap resampling approach, we found no statistically significant difference between HCQ and HCQ plus favipiravir groups in terms of ICU admission. However, compared with the HCQ group, ICU admission rate was statistically significantly higher in the favipiravir group. We obtained the similar results after the sensitivity analysis. Conclusions HCQ with or without favipiravir treatment is associated with reduced risk of ICU admission compared to favipiravir alone in mild to moderate COVID-19 adult patients.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results